Fusion Pharmaceuticals Inc (FUSN)
21.48
+0.02
(+0.12%)
USD |
NASDAQ |
May 20, 13:54
Fusion Pharmaceuticals Accounts Receivable (Quarterly): 0.00 for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.007M |
| September 30, 2023 | 0.041M |
| June 30, 2023 | 0.062M |
| March 31, 2023 | 0.089M |
| December 31, 2022 | 0.061M |
| September 30, 2022 | 0.215M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.177M |
| March 31, 2022 | 0.325M |
| December 31, 2021 | 0.357M |
| September 30, 2021 | 0.30M |
| June 30, 2021 | 0.121M |
| March 31, 2021 | |
| December 31, 2020 | 0.00 |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
--
Minimum
Dec 2020
0.357M
Maximum
Dec 2021
0.135M
Average
0.089M
Median
Mar 2023
Accounts Receivable (Quarterly) Benchmarks
| AstraZeneca PLC | 11.07B |
| Landos Biopharma Inc | -- |
| Perspective Therapeutics Inc | 0.999M |
| Acasti Pharma Inc | -- |
| Aurinia Pharmaceuticals Inc | 24.09M |